Disturbing microtubule-endoplasmic reticulum dynamics by gold nanoclusters for improved triple-negative breast cancer treatment

被引:1
|
作者
Cao, Kai [1 ]
Luo, Kaidi [1 ]
Zheng, Yichen [1 ]
Xue, Liyuan [1 ]
Huo, Wendi [1 ]
Ruan, Panpan [1 ]
Wang, Yuchen [1 ]
Xue, Yilin [1 ]
Yao, Xiuxiu [1 ]
Xia, Dongfang [1 ]
Gao, Xueyun [1 ]
机构
[1] Beijing Univ Technol, Coll Chem & Life Sci, Ctr Excellence Environm Safety & Biol Effects, Dept Chem, Beijing 100124, Peoples R China
基金
中国国家自然科学基金;
关键词
ADJUVANT DOCETAXEL; PROSTATE; COMBINATION; APOPTOSIS; TAXANES; CELLS;
D O I
10.1039/d4tb01492h
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Microtubules are highly dynamic structures, and their dynamic instability is indispensable for not only cell growth and movement, but also stress responses, such as endoplasmic reticulum (ER) stress. Docetaxel, a microtubule targeting agent (MTA), is the first-line drug for cancer treatment by simultaneously promoting microtubule dysregulation- and ER stress-induced cell death. However, it also causes adverse effects and drug resistance, especially in triple-negative breast cancer (TNBC) with a poor prognosis and high mortality rate. In this study, we developed a peptide-templated gold nanocluster, namely GA. GA significantly sensitizes TNBC cells to docetaxel, causing severe cell death. This effect is further validated by a 3D tumor spheroid model. Mechanistically, GA disrupted microtubule dynamic instability, meanwhile promoting PERK-mediated ER stress. Interestingly, ER stress inhibitors profoundly suppressed microtubule dysregulation, suggesting a retrograde regulation of ER stress on microtubules. In vivo, the combined administration of docetaxel and GA significantly suppresses tumor growth while docetaxel alone cannot. GA similarly elevated the level of caspases and PERK within tumors as in vitro. Importantly, GA treatment also profoundly promoted the production of anti-tumor inflammatory cytokines. Collectively, we developed an ER-microtubule regulatory nanomaterial that enhanced the therapeutic effect of docetaxel by elevating tumor cell death and anti-tumor cytokine production, providing a potential supplemental strategy for TNBC treatment. Gold nanocluster GA acts as a docetaxel sensitizer to promote ER stress and microtubule dysregulation, leading to significant tumor cell death and promoting anti-tumor cytokine production in treating triple-negative breast cancer.
引用
收藏
页码:11648 / 11658
页数:11
相关论文
共 50 条
  • [1] Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
    Larsson, Peter
    Pettersson, Daniella
    Olsson, Maxim
    Sarathchandra, Sithumini
    Abramsson, Alexandra
    Zetterberg, Henrik
    Ittner, Ella
    Forssell-Aronsson, Eva
    Kovacs, Aniko
    Karlsson, Per
    Helou, Khalil
    Parris, Toshima Z.
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [2] Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
    Peter Larsson
    Daniella Pettersson
    Maxim Olsson
    Sithumini Sarathchandra
    Alexandra Abramsson
    Henrik Zetterberg
    Ella Ittner
    Eva Forssell-Aronsson
    Anikó Kovács
    Per Karlsson
    Khalil Helou
    Toshima Z. Parris
    Cell Death Discovery, 10
  • [3] Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
    Larsson, Peter
    Pettersson, Daniella
    Olsson, Maxim
    Forssell-Aronsson, Eva
    Kovacs, Aniko
    Karlsson, Per
    Helou, Khalil
    Parris, Toshima Z.
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer
    Lee, Haechan
    Jung, SungWook
    Gong, Gyungyub
    Lim, Bora
    Lee, Hee Jin
    PLOS ONE, 2023, 18 (08):
  • [5] Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics
    Akter, Zakia
    Khan, Fabiha Zaheen
    Khan, Md. Asaduzzaman
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (03) : 316 - 334
  • [6] Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer
    Wang, Yuechen
    Harada-Shoji, Narumi
    Kitamura, Narufumi
    Yamazaki, Yuto
    Ebata, Akiko
    Amari, Masakazu
    Watanabe, Mika
    Miyashita, Minoru
    Tada, Hiroshi
    Abe, Takaaki
    Suzuki, Takashi
    Gonda, Kohsuke
    Ishida, Takanori
    CANCER MEDICINE, 2024, 13 (02):
  • [7] Postneoadjuvant treatment for triple-negative breast cancer
    Trapani, Dario
    Ferraro, Emanuela
    Giugliano, Federica
    Bielo, Luca Boscolo
    Curigliano, Giuseppe
    Burstein, Harold J.
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (06) : 623 - 634
  • [8] Treatment Horizons for Triple-negative Breast Cancer
    Yeo, W.
    HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (02): : 111 - 118
  • [9] Triple-negative breast cancer: is there a treatment on the horizon?
    Yao, Hui
    He, Guangchun
    Yan, Shichao
    Chen, Chao
    Song, Liujiang
    Rosol, Thomas J.
    Deng, Xiyun
    ONCOTARGET, 2017, 8 (01) : 1913 - 1924
  • [10] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5